Wellmune Research
From wellmune.com
Wellmune WGP Cold & Flu Study
Publication:Randomized Phase II Clinical Trials of Wellmune WGP® for Immune Support During Cold and Flu Season. The Journal of Applied Research (2009) 9:20-42.
Presentation:Experimental Biology, 2008 annual meeting, San Diego.
Summary:
A clinical study with the general population demonstrated that Wellmune WGP reduced the incidence of fever and eliminated the need to miss work or school due to cold symptoms.
The randomized, double-blind, placebo-controlled study was conducted last year during the cold/flu season with 40 healthy subjects, aged 18-65. Subjects were treated daily with either 500mg of Wellmune WGP or a placebo for 90 days. Cold/flu symptoms were evaluated by medical staff within 24 hours of onset.
While there were no significant differences in the incidence of symptomatic respiratory infections among the study groups, the duration and severity of symptoms were alleviated in subjects receiving Wellmune WGP.
In the study results, the Wellmune WGP group reported:
• No missed work or school due to colds, compared with 1.38 days of work/school missed for the placebo group. (p = 0.026)
• No incidence of fever, compared with 3.50 incidence in the placebo group. (p = 0.042)
• An increase in quality of life, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2). (p = 0.042)
• No adverse events were detected and no safety concerns were present.
Wellmune WGP 90-Day Lifestyle Stress Study
Publication: Pending
Presentation: Experimental Biology 2010, Anaheim
Summary:
In a study of 122 healthy volunteers (32 men, 90 women 38 + 12y), participants taking 250 mg of Wellmune WGP daily for 12 weeks reported a statistically significant (p<0.05) 58% reduction in upper respiratory tract infection symptoms, compared with individuals taking a placebo.
Using a Profile of Mood States (POMS) psychological survey to assess changes in mental and physical energy levels and overall well-being, the study demonstrated statistically significant benefits for the Wellmune WGP group. These participants rated their overall well-being and vigor 9.5% and 11% higher, respectively, compared with the placebo group. Data for both measures had p values of <0.05.
The study results were consistent with data from other clinical studies demonstrating that Wellmune WGP can naturally enhance immune responses during periods of both high physical and psychological stress.
Wildland Firefighters Stress Study
Presentation:American College of Sports Medicine, May 2008
Publication:Pending
Summary:
In a clinical study, wildland firefighters taking Wellmune WGP® reported better overall health and 23% fewer upper respiratory tract infections (URTI) than those receiving a placebo. The results reflect the ability of Wellmune WGP to protect individuals under demanding physical and psychological conditions from stress-related health challenges.
In a single-blind, random, cross-over design, 54 wildland firefighters from the Bitterroot Hotshots and Great Northern Crews were given Wellmune WGP or placebo for 14 days, followed by a three-day washout period and another 14-day treatment period. During the course of treatments, subjects kept daily health logs recording cold and flu symptoms and overall feelings of well-being. If subjects recorded any cold symptom (runny or stuffy nose, sore throat, coughing, sneezing, colored discharge) or flu symptom (fever, headache, general aches and pains, fatigue and weakness, chest discomfort, cough) for two consecutive days, they were classified with an upper respiratory tract infection.
There was a strong statistical trend favoring the use of Wellmune WGP for the prevention of upper respiratory tract infections. Forty-eight percent of the firefighters experienced an upper respiratory tract infection while taking the placebo, but only 37 percent had an upper respiratory tract infection while taking Wellmune WGP. Additionally, a statistically significant number of firefighters rated their overall health better while taking Wellmune wgp than those who did not.
Lifestyle Stress Study
Publication:Beta 1,3/1,6 Glucan Decreases Upper Respiratory Tract Infection Symptoms and Improves Psychological Well-being in Moderate to Highly-Stressed Subjects. Agro Food Industry Hi-Tech (2010) 21:21-24.
Presentation:American College of Nutrition Annual Meeting, Sept 2007.
Summary:
Highly stressed individuals participating in an independent clinical study reported a significant increase in their general health after taking Wellmune WGP®, a natural compound that activates key immune cells.
A total of 150 people (45 men and 105 women ages 18-65) categorized as leading highly stressful lives completed the double-blind, placebo-controlled study. The participants received either Wellmune WGP or a placebo daily for four weeks. The study measured both stress-related incidence of upper respiratory tract infection symptoms (i.e. cold, flu) and psychological well-being, including levels of vigor, tension, mental clarity and fatigue.
High-stress subjects taking 250 mg of Wellmune WGP daily reported a 41% increase in general health when compared with the placebo group over the four-week study period. (All reported data is statistically significant at the p<0.05 level.) In comparison with the placebo group, the Wellmune WGP group reported a:
42% increase in vigor
38% reduction in fatigue
19% reduction in tension
15% reduction in stress-induced confusion
The Wellmune WGP group also reported fewer symptoms associated with upper respiratory tract infections, including nasal congestion, runny nose, sore throat, sneezing, cough, fatigue, headache, general malaise and body aches. After four weeks of treatment, 28% of the placebo group reported URTI symptoms, compared with 8% in the groups taking Wellmune WGP.
Study Design
Subjects were selected for the study using a 15-question survey that assessed individual levels of perceived stress. This screening method was successfully used in six prior clinical studies. The subjects were randomly administered either Wellmune wgp or a placebo for four weeks.
The physical health of the study subjects was evaluated based on reported incidence of URTI-related symptoms. Subjects were asked to score their health during the supplementation using a 1-to-10 scale (1=worse, 10-better) and similarly rate their overall health status.
The psychological well-being of the study participants was measured using a Profile of Mood States (POMS) questionnaire. POMS is a validated psychometric test that measures six primary mood states: tension, depression, anger, fatigue, vigor and confusion. The POMS profile method has been employed in more than 2,900 health studies.
Marathoner Runner Stress Study, 2007
Publication:Effect of Beta 1, 3/1, 6 Glucan on Upper Respiratory Tract Infection Symptoms and Mood State in Marathon Athletes. Journal of Sports Science and Medicine (2009). 8:509-515.
Presentation:American College of Nutrition Annual Meeting, Sept 2007.
Summary:
In a double-blind, placebo-controlled study, marathon runners taking Wellmune WGP® reported significant physical and psychological health benefits.
The physical health results demonstrated a significant decrease in upper respiratory tract infection (URTI) symptoms at two and four weeks for subjects taking 250 mg of Wellmune WGP daily. Sixty-eight percent of runners in the placebo group reported URTI symptoms at 2 weeks compared with only 32% for the group taking Wellmune WGP. At four weeks, 24% of the placebo group reported URTI symptoms compared with 8% of the Wellmune WGP group.
When asked how the supplement regimen was affecting their overall health, participants consuming 250 mg of Wellmune WGP daily reported 38% higher scores compared with the placebo group. In addition, the Wellmune subjects reported significantly better scores on a variety of mood states, including a:
22% increase in vigor**
48% reduction in fatigue
38% reduction in tension
38% reduction in stress-related confusion
**500 mgs of Wellmune WGP
Study Design:
The double-blind, placebo-controlled study included 75 marathon runners (35 men, 40 women) ages 18-53 (mean age 36 years) who were recruited from the 2007 Carlsbad Marathon in California. During the four-week period following the marathon, subjects consumed a placebo or Wellmune WGP, a natural carbohydrate that activates key immune cells to more quickly recognize and kill foreign challenges.
The study measured the psychological states of the participants using a Profile of Mood States (POMS) questionnaire. The POMS profile method is a validated psychometric test that measures six primary moods states (vigor, fatigue, tension, confusion, depression and anger). The POMS profile has been used in more than 2,900 health studies.